HIF-2a
Arcus Biosciences Advances Promising Kidney Cancer Drug Casdatifan After Gilead Opts Out
Arcus Biosciences, casdatifan, HIF-2a inhibitor, kidney cancer, clear cell renal cell carcinoma (ccRCC), Gilead Sciences, clinical trial data, $150 million stock offering